Clinical value of serum trophoblast cell surface protein 2 (TROP2) antibody in non-small-cell lung cancer patients. (16th November 2016)

• Record Type: Journal Article
• Authors: Zheng, Zhuan; Dong, Xue-Jun
• Is Part Of: Biomarkers. Volume 21:Number 8(2016)
• Page Start: 739
• Page End: 742
• Publication Date: 2016-11-16
• Subjects: Antibodies -- clinical value -- non-small cell lung cancer -- trophoblast cell surface protein 2; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2016.1201532
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Objective: This study was to explore the clinical role of serum trophoblast cell surface protein 2 (TROP2) antibody in patients with non-small-cell lung cancer (NSCLC). Materials and methods: We collected serum specimens from 117 NSCLC patients, 40 benign lung disease patients, and 60 healthy controls. TROP2 antibody concentrations were measured using enzyme-linked immunosorbent assay. Results: Serum TROP2 antibody levels were higher in the NSCLC group compared to the control group ( p < 0.001). TROP2 antibody, at a cutoff value of 9.8 U/ml, showed good diagnostic performance for NSCLC. Conclusion: Measurement of TROP2 antibody might have diagnostic value for patients with NSCLC.